HHS Fights Back to Keep Expanded 340B Drug Discounts
The drug industry scored a victory last month against the Obama administration's plans to give hospitals millions of dollars in discounts through the 340B program on orphan drugs. But HHS is sticking to its position that the Patient Protection and Affordable Care Act promises breaks on the expensive drugs when they're used for non-orphan indications.
Ventana and MedImmune to Develop a PD-L1 Assay To Aid Patient Enrollment in Immunotherapy Trials
Ventana Medical Systems, Inc. and MedImmune today announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that will enroll only patients who express PD-L1 as determined by the VENTANA assay.
U.S. House Votes to Ensure Speedier Care for Vets
The U.S. House of Representatives passed legislation that makes it easier for patients to receive VA-paid treatment from their local doctors as a way to combat the longer waits for care at Veterans Affairs facilities.
Federal Views Diverge on Proper Use of Painkillers
The recent conversation regarding the abuse of prescription drugs that provide pain relief has some federal government officials calling this epidemic a "growing national crisis". While prescriptions such as Vicodin, OxyContin and other opioid drugs help patients with chronic pain, the White House is asking doctors to curtail their use of prescription opioids.
Michigan To Reward Medicaid Enrollees Who Take ‘Personal Responsibility’
After an exceedingly high Medicaid enrollment this spring, Michigan became the second state to offer incentives and rewards for participants who agree to do health risk assessments with their physicians once a year as well as work to take the proper steps that improve their overall health.
CYRAMZA Meets Secondary Endpoints in Phase 3 REACH Trial for HCC
CYRAMZA™ (ramucirumab)did not meet its primary endpoint; overall survival favored the CYRAMZA arm but was not statistically significant, in patients with hepatocellular carcinoma, but meaningful improvements in key secondary endpoints of progression-free survival, overall response rate and time to progression were observed.
Sebelius Hands Reins to Successor
Kathleen Sebelius handed leadership of the Health and Human Services Department to her successor on Monday and wished new Secretary Sylvia Matthews Burwell the best of luck.